

UNITED STATES PATENT AND TRADEMARK OFFICE

DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE
BOARD OF PATENT APPEALS AND INTERFERENCES
BOX INTERFERENCE, WASHINGTON, D.C. 20231

Filed by: Judge Michael P. Tierney

Telephone: 571-272-9797 Facsimile: 571-273-0042

MAILED

AUG 1 5 2006

PAT. & T.M. OFF.CE BOARD OF PATENT APPEALS AND INTERFERENCES Applicants: YU

Application No.: 09/589,288

Filed: 06/08/00

For: Methods of inhibiting B lymphocytes using

antibodies to neutrokine-alpha

The above-identified application or patent has been forwarded to the Board of Patent Appeals and Interferences because it is adjudged to interfere with another application or patent. An interference has been declared. The interference is designated as No. 105,485.

Notice is hereby given the parties of the requirement of the law for filing in the Patent and Trademark Office a copy of any agreement "in connection with or in contemplation of the termination of the interference." 35 U.S.C. § 135(c).

/Michael P. Tierney/ MICHAEL P. TIERNEY Administrative Patent Judge Mail Stop Interference P.O. Box 1450 Alexandria Va 22313-1450

Filed August 15, 2006

Tel: 571-272-4683 Fax: 571-273-0042

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

JEFFREY BROWNING, CHRISTINE AMBROSE, FABIENNE MacKAY, JURG TSCHOPP, and PASCAL SCHNEIDER, Junior Party (U.S. Patent No. 6,869,605),

v.

GUO-LIANG YU, REINHARD EBNER, and JIAN NI Senior Party (U.S. Application No. 09/589,288).

Patent Interference No. 105,485 (MPT) (Technology Center 1600)

DECLARATION - Bd.R. 203(b)1

- 1 Part A. Declaration of interference
- 2 An interference is declared (35 U.S.C. '135(a)) between the above-identified parties.
- 3 Details of the application(s), patent (if any), reissue application (if any), count(s) and claims

¹ "Bd.R. x" may be used as shorthand for "37 C.F.R. '41.x". 69 Fed. Reg. 49960, 49961 (12 Aug. 2004).

- 1 designated as corresponding or as not corresponding to the count(s) appear in Parts E and F of
- 2 this DECLARATION.
- 3 Part B. Judge managing the interference
- 4 Administrative Patent Judge Michael P. Tierney has been designated to manage the
- 5 interference. Bd. R. 104(a).
- 6 Part C. Standing order
- 7 A Trial Section STANDING ORDER [SO] (Paper 2) accompanies this DECLARATION.
- 8 The STANDING ORDER applies to this interference.
- 9 Part D. Initial conference call
- A telephone conference call to discuss the interference is set for 2:00 p.m. on October
- 11 10, 2006 (the Board will initiate the call).
- No later than four business days prior to the conference call, each party shall file and
- 13 serve (SO §§ 10.1 & 105) a list of the motions (Bd. R. 120; Bd. R. 204; SO §§ 104.2.1, 120
- 14 & 204) the party intends to file.
- 15 A sample schedule for taking action during the motion phase appears as Form 2 in the
- 16 STANDING ORDER. Counsel are encouraged to discuss the schedule prior to the conference
- 17 call and to agree on dates for taking action. A typical motion period lasts approximately eight
- 18 (8) months. Counsel should be prepared to justify any request for a shorter or longer period.

1	Part E. Identification and order of the parties				
2		Junior Party			
3	Named inventors:	JEFFREY BROWNING, BROOKLINE, MA			
4		CHRISTINE AMBROSE, READING, MA			
5		FABIENNE MacKAY, VAUCLUSE, AUSTRALIA			
6		JURG TSCHOPP, EPALINGES, SWITZERLAND			
7		PASCAL SCHNEIDER, EPALINGES, SWITZERLAND			
8	Involved Patent:	U.S. Patent No. 6,869,605, issued on March 22, 2005,			
9		based upon U.S. Application No. 09/911,777			
10	Title:	BAFF, INHIBITORS THEREOF AND THEIR USE IN			
11		THE MODULATION OF B-CELL RESPONSE			
12	Assignee:	Biogen Idec MA Inc.			
13					
14		Senior Party			
15	Named Inventors:	GUO-LIANG YU, BERKELEY, CA			
16		REINHARD EBNER, GAITHERSBURG, MD			
17		JIAN NI, ROCKVILLE, MD			
18	Involved Application:	U.S. Application No. 09/589,288, filed June 8, 2000			
19	Title:	METHODS OF INHIBITING B LYMPHOCYTES USING			
20		ANTIBODIES TO NEUTROKINE-ALPHA			
21	Assignee:	Human Genome Sciences, Inc.			

1	The senior party is assigned exhibit numbers 1001-1999. The junior party is assigned						
2	exhibit numbers 2001-2999. Bd. R. 154(c)(1); SO § 154.2.1. The senior party is responsible for						
3	initiating settlement discussions. SO § 126.1.						
4							
5	Part F. Count and claims of the parties						
6	Count 1						
7	A method according to claim 1 of U.S. Patent No. 6,869,605 or claim 195 of U.S.						
8	Application No. 09/589,288.						
9							
10	The claims of the parties are:						
11	Browning, U.S. Patent No. 6,869,605: 1-14						
12	Yu, U.S. Application No. 09/589,288: 195-207						
13							
14	The claims of the parties which correspond to Count 1 are:						
15	Browning, U.S. Patent No. 6,869,605: 1-14						
16	Yu, U.S. Application No. 09/589,288: 195-207						
17							
18	The claims of the parties which do not correspond to Count 1, and therefore are not						
19	involved in the interference, are:						
20	Browning, U.S. Patent No. 6,869,605: None						
21	Yu, U.S. Application No. 09/589,288: None						

22

1	The p	The parties are accorded the following benefit for Count 1:					
2		Browning is accorded priority benefit of the following applications:					
3	i)	PCT/US00/01788, filed January 25, 2000;					
4	ii)	U.S. Provisional Application No. 60/143,288, filed July 9, 1999;					
5	iii)	U.S. Provisional Application No. 60/117,169, filed January 25, 1999.					
6							
7		Yu is accorded priority benefit of the following applications:					
8	i)	U.S. Application No. 09/507,968, filed February 22, 2000, now U.S. Patent No.					
9		6,812,327, issued November 2, 2004;					
10	ii)	U.S. Provisional Application No. 60/122,388, filed March 2, 1999;					
11	iii)	U.S. Application No. 09/255,794, filed February 23, 1999, issued as U.S. Patent					
12		No. 6,716,576 on April 6, 2004;					
13	iv)	U.S. Application No. 09/005,874, filed January 12, 1998, issued as U.S. Patent					
14		No. 6,689,579 on February 10, 2004.					
15							

1	Part G. Heading to be used on papers
2 3 4	The following heading must be used on all papers filed in this interference, see SO § 106.1.1:
5 6	UNITED STATES PATENT AND TRADEMARK OFFICE
7	DEPONE THE DOADD OF DATENT ADDEALS
8 9	BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES
10	AND INTERFERENCES
11	
12	JEFFREY BROWNING, CHRISTINE AMBROSE,
13	FABIENNE MacKAY, JURG TSCHOPP, and PASCAL SCHNEIDER,
14	Junior Party
15	(U.S. Patent No. 6,869,605),
16	
17	v.
18	
19	GUO-LIANG YU, REINHARD EBNER,
20	and JIAN NI
21 22	Senior Party (U.S. Application No. 09/589,288).
	(0.5. Application 140. 03/303,288).
24 25	
26	Patent Interference No. 105,485 (MPT)
27	(Technology Center 1600)
28	(20020018)
30	
31	
32	Part H. Order form for requesting file copies
33	When requesting copies of files, use of SO Form 4 will greatly expedite processing of the
34	request. Please attach a copy of Parts E and F of this DECLARATION with a hand-drawn circle
35	around the patents and applications for which a copy of a file wrapper is requested.
36	
37	/Michael P. Tierney/
38 39	MICHAEL P. TIERNEY Administrative Patent Judge
.):4	Auminisualive falent juuze

1 Enc: 2 Copy of STANDING ORDER 3 Copy U.S. Patent 6,869,605 4 Copy of claims of U.S. Application No. 09/589,288 5 6 Revised 3 January 2006 7 8 9 cc (via overnight delivery): 10 11 Attorney for **BROWNING**: 12 13 FINNEGAN, HENDERSON, FARABOW, **GARRETT & DUNNER LLP** 14 15 901 New York Avenue, N.W. Washington, D.C. 20001-4413 16 17 18 Attorney for YU: 19 20 HUMAN GENOME SCIENCES, INC. Intellectual Property Department 21 14200 Shady Grove Road 22 Rockville, MD 20850 23

INTERFERENCE DIGEST

Interference No.		105,485		Paper No.						
Name: Guo-Liang Yu et al.										
Serial No.:	09/589	,288	Patent No.							
Title: Methods of inhibiting B lymphocytes using antibodies to neutrokine-alpha										
Filed: 06/08/00										
Interference with Browning et al.										
DECISION ON MOTIONS										
Administrative Patent Judge,					Dated,					
	··									
			TZUNI A	AL DECISION	r					
Board of Patent Appeals and Interferences,Dated,										
Count					Dated,					
Court,	Dated,									
REMARKS										
	-									

This should be placed in each application or patent involved in interference in addition to the interference letters.